[Ip-health] MSF intervention on WHO EB agenda item 132/18 - Global Vaccine Action Plan

Joanna Keenan-Siciliano joanna.l.keenan at gmail.com
Fri Jan 25 05:49:11 PST 2013


Executive Board 132; Agenda item 132/18
Global Vaccine Action Plan
Intervention by Michelle Childs, Médecins Sans Frontières International



Médecins Sans Frontières welcomes the focus on immunisation brought by the
Decade of Vaccines.

We are concerned, however, that the Global Vaccine Action Plan’s draft
monitoring and evaluation framework omits *two essential targets*.

First, the framework is not ambitious enough in terms of bringing new
vaccine delivery technologies to immunisation programmes. In places where
MSF works, we see that the current tools are inadequate for reaching
children who are disproportionately affected by vaccine-preventable
diseases: they require refrigeration, are difficult to transport, and need
trained health staff. More than 112 million children remained unimmunised
in the last five years. The question of vaccine adaptability is therefore
critical. We need new vaccine products that can be delivered through
innovative technologies, more suited to the places where vaccines are most
needed – needle-free, oral, heat-stable vaccines. Yet the monitoring and
evaluation framework aims for *only one* “new platform delivery technology”
by 2020. This is not ambitious enough.

Second, the Global Vaccine Action Plan must consider vaccine affordability.
The cost of fully vaccinating a child has increased by 2,700% since 2001,
and promises to increase. Many member states at the WHA last year
articulated concerns about the sustainability of immunisation programmes,
calling for greater affordability.  It is alarming that the monitoring and
evaluation framework contains *no indicator at all* on vaccine pricing.
Initial estimates put the cost of the Decade of Vaccines at between 42 and
51 *billion* dollars. A significant portion is due to the cost of vaccines
themselves; we are therefore compelled to track prices. An appropriate
indicator would be a percentage change of the cost of a fully-immunised
child as per WHO-recommended EPI schedule.

MSF therefore urges member states to call for a more ambitious target on
new delivery technologies, and to insist on including a vaccine pricing
indicator. This would acknowledge the challenges faced by countries in
implementing vaccination programmes, and put concrete metrics to critical
aspects for the Decade of Vaccines.


Joanna Keenan
Press Officer
Médecins Sans Frontières - Access Campaign
P: +41 22 849 87 45
M: +41 79 203 13 02
E: joanna.keenan[at]geneva.msf.org
T: twitter.com/joanna_keenan

msfaccess.org
twitter.com/MSF_access
facebook.com/MSFaccess



More information about the Ip-health mailing list